National Center for Clinical Laboratories, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Hospital/National Center of Gerontology, No. 1 Dahua Road, Dongdan, Beijing, 100730, People's Republic of China.
Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing Hospital, Beijing, People's Republic of China.
Clin Epigenetics. 2023 Oct 19;15(1):168. doi: 10.1186/s13148-023-01585-8.
Detecting organ and tissue damage is essential for early diagnosis, treatment decisions, and monitoring disease progression. Methylation-based assays offer a promising approach, as DNA methylation patterns can change in response to tissue damage. These assays have potential applications in early detection, monitoring disease progression, evaluating treatment efficacy, and assessing organ viability for transplantation. cfDNA released into the bloodstream upon tissue or organ injury can serve as a biomarker for damage. The epigenetic state of cfDNA, including DNA methylation patterns, can provide insights into the extent of tissue and organ damage.
Firstly, this review highlights DNA methylation as an extensively studied epigenetic modification that plays a pivotal role in processes such as cell growth, differentiation, and disease development. It then presents a variety of highly precise 5-mC methylation detection techniques that serve as powerful tools for gaining profound insights into epigenetic alterations linked with tissue damage. Subsequently, the review delves into the mechanisms underlying DNA methylation changes in organ and tissue damage, encompassing inflammation, oxidative stress, and DNA damage repair mechanisms. Next, it addresses the current research status of cfDNA methylation in the detection of specific organ tissues and organ damage. Finally, it provides an overview of the multiple steps involved in identifying specific methylation markers associated with tissue and organ damage for clinical trials. This review will explore the mechanisms and current state of research on cfDNA methylation-based assay detecting organ and tissue damage, the underlying mechanisms, and potential applications in clinical practice.
检测器官和组织损伤对于早期诊断、治疗决策和监测疾病进展至关重要。基于甲基化的检测方法提供了一种很有前途的方法,因为 DNA 甲基化模式可以响应组织损伤而发生变化。这些检测方法在早期检测、监测疾病进展、评估治疗效果以及评估移植器官的活力方面具有潜在的应用价值。组织或器官损伤时释放到血液中的 cfDNA 可作为损伤的生物标志物。cfDNA 的表观遗传状态,包括 DNA 甲基化模式,可以提供有关组织和器官损伤程度的深入了解。
首先,本综述强调了 DNA 甲基化作为一种广泛研究的表观遗传修饰,在细胞生长、分化和疾病发展等过程中起着关键作用。然后介绍了多种高度精确的 5-mC 甲基化检测技术,这些技术是深入了解与组织损伤相关的表观遗传改变的有力工具。接着,综述探讨了器官和组织损伤中 DNA 甲基化变化的机制,包括炎症、氧化应激和 DNA 损伤修复机制。接下来,讨论了 cfDNA 甲基化在检测特定器官组织和器官损伤中的当前研究现状。最后,概述了在临床试验中确定与组织和器官损伤相关的特定甲基化标记物的多个步骤。本综述将探讨 cfDNA 甲基化基于检测的器官和组织损伤的机制和研究现状,以及在临床实践中的潜在应用。